Table 1.

Description of trials that provided samples for the molecular study^*

	Antimalarial regimens studied
Baseline study characteristics	CQ+SP vs. AQ+SP vs. AS+AQ†	AL vs. AS+AQ†	AL vs. DP‡
Study period	2002–04	2004–05	2007–12
Age at enrollment	≥ 6 months	1–10 years	4–12 months
Number of participants	347	403	351
Median age (years)	1.27	1.83	0.98
Geometric mean parasite density	18,484/μL	22,071/μL	16,349/μL
Samples successfully genotyped	189/198 (95%)	188/201 (93%)	561/584 (96%)

^*CQ = chloroquine; SP = sulfadoxine-pyrimethamine; AQ = amodiaquine; AL = artemether-lumefantrine; DP = dihydroartemisinin-piperaquine.

^†Pretreatment samples obtained from clinical studies.³¹,³²

^‡Samples from all first episodes and recurrent episodes ≥ 84 days after prior treatment.³³